Bukowski Rm
Impact in
- Hematology top 5%
- Blood groups and transfusion
- Platelet Disorders and Treatments
- Nephrology top 5%
- Renal Diseases and Glomerulopathies
Papers in
- Oncology 10
- Cancer Treatment and Pharmacology 2
- Colorectal Cancer Treatments and Studies 2
-
- Renal cell carcinoma treatment 3
- Gastric Cancer Management and Outcomes 2
- Co-authors
- Hewlett Js (6 shared papers)Harris Jw (1 shared paper)Weick Jk (3 shared papers)R. Gahbauer (1 shared paper)Sewa S. Legha (1 shared paper)John H. Saiki (1 shared paper)Robert M. OʼBryan (1 shared paper)Pontes Je (1 shared paper)
- Journals
- PubMed (18 papers)
- Partner nations
- United States
In The Last Decade
Bukowski Rm
18 papers receiving 388 citations
Peers
Comparison fields: 5 of 57
- Hematology 154
- Nephrology 90
- Immunology 235
- Genetics 71
- Oncology 93
Countries citing papers authored by Bukowski Rm
This map shows the geographic impact of Bukowski Rm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bukowski Rm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bukowski Rm more than expected).
Fields of papers citing papers by Bukowski Rm
This network shows the impact of papers produced by Bukowski Rm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bukowski Rm. The network helps show where Bukowski Rm may publish in the future.
Co-authors
The 25 scholars most cited alongside Bukowski Rm, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Thrombotic thrombocytopenic purpura: a review. | 1982 | 118 |
| 2 | Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura. | 1976 | 112 |
| 3 | Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. | 2000 | 40 |
| 4 | Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozotocin. | 1979 | 30 |
| 5 | Simultaneous treatment with cisplatin and radiation therapy for advanced solid tumors: a pilot study. | 1981 | 28 |
| 6 | Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas. | 1980 | 25 |
| 7 | Treatment of severe aplastic anemia with antithymocyte globulin. | 1982 | 13 |
| 8 | Phase II trial of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group Study. | 1982 | 12 |
| 9 | Phase Ia-Ib trial of an anti-GD3 monoclonal antibody in combination with interferon-alpha in patients with malignant melanoma. | 1990 | 9 |
| 10 | Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study. | 1983 | 8 |
| 11 | Neo-adjuvant intra-arterial chemotherapy in locally advanced bladder cancer. | 1990 | 6 |
| 12 | Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, doxorubicin, and mitomycin for residual localized gastric adenocarcinoma: a Southwest Oncology Group pilot study. | 1983 | 5 |
| 13 | Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study. | 1987 | 5 |
| 14 | Acute colonic pseudo-obstruction associated with interleukin-2 therapy. | 1991 | 4 |
| 15 | Chemotherapy of metastatic gastrointestinal neoplasms with 5-fluorouracil and streptozotocin. | 1977 | 4 |
| 16 | Biologic therapy in patients receiving salvage treatment. | 1994 | 3 |
| 17 | Mitoguazone in advanced renal carcinoma: a phase II trial of the Southwest Oncology Group. | 1983 | 2 |
| 18 | Phase II trial of Baker's antifol in metastatic renal cell carcinoma: a Southwest Oncology Group Study. | 1980 | 2 |
About Bukowski Rm
Bukowski Rm is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Epidemiology and Hematology, having authored 18 papers that have together received 426 indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (3 papers), Neuroendocrine Tumor Research Advances (3 papers), Cancer Treatment and Pharmacology (2 papers), Neuroblastoma Research and Treatments (2 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers), Hematological disorders and diagnostics (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Gastric Cancer Management and Outcomes (2 papers). The work is most often cited by research in Hematology (154 citations), Nephrology (90 citations), Immunology (235 citations), Genetics (71 citations) and Oncology (93 citations). Bukowski Rm has collaborated with scholars based in United States. Frequent co-authors include Hewlett Js, Harris Jw, Weick Jk, R. Gahbauer, Sewa S. Legha, John H. Saiki, Robert M. OʼBryan, Pontes Je, James E. Montie and G Chéchile. Their work appears in journals such as PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.